Published in Endocr Relat Cancer on December 21, 2010
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun (2014) 1.95
miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response. Nat Med (2011) 1.94
miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1. Mol Cancer Res (2010) 1.54
MiR-200, a new star miRNA in human cancer. Cancer Lett (2013) 1.50
MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin (2014) 1.40
Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer. BMC Cancer (2012) 1.27
Restoration of miR-200c to ovarian cancer reduces tumor burden and increases sensitivity to paclitaxel. Mol Cancer Ther (2012) 1.26
Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer. PLoS One (2014) 1.26
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res (2012) 1.22
MiR-200c and HuR in ovarian cancer. BMC Cancer (2013) 1.18
Microtubules and their role in cellular stress in cancer. Front Oncol (2014) 1.15
Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. Oncotarget (2011) 1.14
miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1. Am J Pathol (2012) 1.13
MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features. World J Surg Oncol (2012) 1.12
An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription. Nucleic Acids Res (2011) 1.08
The Role of microRNAs in the Tumorigenesis of Ovarian Cancer. Front Oncol (2013) 1.08
miR-200c inhibits invasion, migration and proliferation of bladder cancer cells through down-regulation of BMI-1 and E2F3. J Transl Med (2014) 1.01
Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker. BMC Cancer (2014) 0.99
Current status and implications of microRNAs in ovarian cancer diagnosis and therapy. J Ovarian Res (2012) 0.98
The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2. Oncotarget (2015) 0.97
MiR-200b expression in breast cancer: a prognostic marker and act on cell proliferation and apoptosis by targeting Sp1. J Cell Mol Med (2015) 0.96
miR-200b as a prognostic factor in breast cancer targets multiple members of RAB family. J Transl Med (2014) 0.95
Overexpression of microRNA-200c predicts poor outcome in patients with PR-negative breast cancer. PLoS One (2014) 0.90
Epigenomics of ovarian cancer and its chemoprevention. Front Genet (2011) 0.89
Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. Oncotarget (2014) 0.89
RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma. Br J Cancer (2012) 0.89
MicroRNA: a new and promising potential biomarker for diagnosis and prognosis of ovarian cancer. Cancer Biol Med (2015) 0.89
Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. J Oncol (2012) 0.88
miR-124 and miR-506 inhibit colorectal cancer progression by targeting DNMT3B and DNMT1. Oncotarget (2015) 0.87
Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer. Oncotarget (2016) 0.86
Targeting estrogen-related receptor alpha inhibits epithelial-to-mesenchymal transition and stem cell properties of ovarian cancer cells. Mol Ther (2014) 0.86
Application of microRNA in diagnosis and treatment of ovarian cancer. Biomed Res Int (2014) 0.86
Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLoS One (2014) 0.85
The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells. Mol Oncol (2015) 0.84
The Clinical Significance of MiR-429 as a Predictive Biomarker in Colorectal Cancer Patients Receiving 5-Fluorouracil Treatment. Med Sci Monit (2016) 0.81
The miR-200 Family: Versatile Players in Epithelial Ovarian Cancer. Int J Mol Sci (2015) 0.81
Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer. Pancreas (2013) 0.81
MicroRNA-200a suppresses metastatic potential of side population cells in human hepatocellular carcinoma by decreasing ZEB2. Oncotarget (2015) 0.81
MicroRNAs: key players of taxane resistance and their therapeutic potential in human cancers. J Cell Mol Med (2013) 0.81
Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma. Oncotarget (2015) 0.81
MicroRNA-200a regulates Grb2 and suppresses differentiation of mouse embryonic stem cells into endoderm and mesoderm. PLoS One (2013) 0.80
Stressed tumor cell, chemosensitized cancer. Nat Med (2011) 0.80
Nanoparticle-mediated drug delivery for treating melanoma. Nanomedicine (Lond) (2015) 0.79
Prognostic Value and Clinicopathology Significance of MicroRNA-200c Expression in Cancer: A Meta-Analysis. PLoS One (2015) 0.79
Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: evidence that miR200a-3p is regulated by O⁶-methylguanine methyltransferase and promotes temozolomide responsiveness. Cancer Biol Ther (2014) 0.78
Molecular epigenetics in the management of ovarian cancer: are we investigating a rational clinical promise? Front Oncol (2014) 0.78
miR-200c Regulation of Metastases in Ovarian Cancer: Potential Role in Epithelial and Mesenchymal Transition. Front Pharmacol (2016) 0.77
MicroRNAs in Gynecological Cancers: Small molecules with big implications. Cancer Lett (2017) 0.76
Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma. Expert Rev Mol Diagn (2016) 0.75
Prognostic Role of the MicroRNA-200 Family in Various Carcinomas: A Systematic Review and Meta-Analysis. Biomed Res Int (2017) 0.75
MicroRNA-429 inhibits gastric cancer migration and invasion through the downregulation of specificity protein 1. Oncol Lett (2017) 0.75
miR-506 inhibits cell proliferation and invasion by targeting TET family in colorectal cancer. Iran J Basic Med Sci (2016) 0.75
Downregulation of miR-429 contributes to the development of drug resistance in epithelial ovarian cancer by targeting ZEB1. Am J Transl Res (2017) 0.75
miR-200b is a key regulator of tumor progression and metabolism targeting lactate dehydrogenase A in human malignant glioma. Oncotarget (2016) 0.75
Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer. PLoS One (2017) 0.75
MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer. Sci Rep (2017) 0.75
Prognostic role of miR-200c in various malignancies: a systematic review and meta-analysis. Int J Clin Exp Med (2015) 0.75
Prognostic significance of microRNA-200c in various types of cancer: An updated meta-analysis of 34 studies. Mol Clin Oncol (2016) 0.75
MicroRNA-200b inhibits pituitary tumor cell proliferation and invasion by targeting PKCα. Exp Ther Med (2017) 0.75
The miR-200 family in ovarian cancer. Oncotarget (2017) 0.75
Members of the microRNA-200 family are promising therapeutic targets in cancer. Exp Ther Med (2017) 0.75
Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res (2008) 6.95
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol (2011) 2.75
Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biol (2012) 2.70
SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol (2010) 2.42
Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res (2006) 2.34
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet (2011) 2.29
FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res (2006) 2.15
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol (2011) 2.14
Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol (2009) 2.11
Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat (2006) 2.10
Angiogenesis and ovarian cancer. Clin Transl Oncol (2009) 2.09
Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol (2007) 2.09
Adenomatoid tumors of the uterus: an analysis of 60 cases. Int J Gynecol Pathol (2002) 1.80
Cyclin D1 gene (CCND1) mutations in endometrial cancer. Oncogene (2003) 1.74
PupaSNP Finder: a web tool for finding SNPs with putative effect at transcriptional level. Nucleic Acids Res (2004) 1.74
Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res (2009) 1.68
Tumoral and tissue-specific expression of the major human beta-tubulin isotypes. Cytoskeleton (Hoboken) (2010) 1.64
The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors. PLoS Genet (2009) 1.57
Comparison of molecular analysis and histopathology for axillary lymph node staging in primary breast cancer: results of the B-CLOSER-I study. Diagn Mol Pathol (2012) 1.56
Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res (2009) 1.53
KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One (2009) 1.50
Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas. Cancer Res (2008) 1.48
Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer. Oncology (2009) 1.47
Pediatric paraganglioma: an early manifestation of an adult disease secondary to germline mutations. Pediatr Blood Cancer (2006) 1.47
Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene (2002) 1.46
Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res (2007) 1.45
Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. Carcinogenesis (2005) 1.44
Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer (2003) 1.43
Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene (2004) 1.39
90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial? Eur J Cancer (2008) 1.39
Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocr Relat Cancer (2010) 1.38
An 8-gene qRT-PCR-based gene expression score that has prognostic value in early breast cancer. BMC Cancer (2010) 1.34
Comparison of gene expression profiling by reverse transcription quantitative PCR between fresh frozen and formalin-fixed, paraffin-embedded breast cancer tissues. Biotechniques (2010) 1.31
ERCC4 associated with breast cancer risk: a two-stage case-control study using high-throughput genotyping. Cancer Res (2006) 1.29
Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas. EMBO Mol Med (2011) 1.28
Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol (2010) 1.26
Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA (2010) 1.22
MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res (2012) 1.22
Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res (2011) 1.21
Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. J Clin Pathol (2006) 1.20
Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. J Pathol (2014) 1.19
Genetics of pheochromocytoma and paraganglioma in Spanish patients. J Clin Endocrinol Metab (2009) 1.18
Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc Natl Acad Sci U S A (2007) 1.16
MAX and MYC: a heritable breakup. Cancer Res (2012) 1.15
Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Hum Mol Genet (2013) 1.14
Implications of oxidative stress and cell membrane lipid peroxidation in human cancer (Spain). Cancer Causes Control (2004) 1.13
Evaluating HapMap SNP data transferability in a large-scale genotyping project involving 175 cancer-associated genes. Hum Genet (2005) 1.13
Abnormal ezrin localization is associated with clinicopathological features in invasive breast carcinomas. Breast Cancer Res Treat (2006) 1.12
Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res (2003) 1.11
Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome. J Clin Endocrinol Metab (2009) 1.09
Urinary tract endometriosis: clinical, diagnostic, and therapeutic aspects. Urology (2008) 1.08
Association studies in thyroid cancer susceptibility: are we on the right track? J Mol Endocrinol (2011) 1.06
Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Hum Mol Genet (2013) 1.05
Abnormalities of E- and P-cadherin and catenin (beta-, gamma-catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J Pathol (2003) 1.04
Shorter telomere length is associated with increased ovarian cancer risk in both familial and sporadic cases. J Med Genet (2012) 1.04
Head and neck paragangliomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. J Clin Endocrinol Metab (2009) 1.04
Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. Clin Cancer Res (2004) 1.04
Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. Hum Pathol (2006) 1.04
Polymorphisms in RET and its coreceptors and ligands as genetic modifiers of multiple endocrine neoplasia type 2A. Cancer Res (2006) 1.04
Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. J Med Genet (2013) 1.03
Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy. Clin Cancer Res (2012) 1.03
Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J Clin Endocrinol Metab (2007) 1.02
Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma. J Pathol (2003) 1.02
Association study of 69 genes in the ret pathway identifies low-penetrance loci in sporadic medullary thyroid carcinoma. Cancer Res (2007) 1.01
Molecular characterization of Ypi1, a novel Saccharomyces cerevisiae type 1 protein phosphatase inhibitor. J Biol Chem (2003) 1.01
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clin Cancer Res (2013) 1.00
Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency. J Clin Endocrinol Metab (2014) 0.97
Tumour-microenvironmental interactions: paths to progression and targets for treatment. Semin Cancer Biol (2010) 0.97
Aurora kinases as prognostic biomarkers in ovarian carcinoma. Hum Pathol (2009) 0.97
Are we overestimating the penetrance of mutations in SDHB? Hum Mutat (2010) 0.97
Evaluation of the BRCA1 interacting genes RAP80 and CCDC98 in familial breast cancer susceptibility. Breast Cancer Res Treat (2008) 0.96